Published in final edited form as:

Bioorg Med Chem Lett. 2011 May 15; 21(10): 2840–2844. doi:10.1016/j.bmcl.2011.03.091.

New monoterpene glycosides and phenolic compounds from *Distylium racemosum* and their inhibitory activity against ribonuclease H

Jeong Ah Kim^a, Seo Young Yang^a, Anthony Wamiru^{b,c}, James B. McMahon^b, Stuart F. J. Le Grice^d, John A. Beutler^b, Young Ho Kim^{a,b,*}

^aCollege of Pharmacy, Chungnam National University, Daejeon 305-764, Republic of Korea

^bMolecular Targets Laboratory, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA

^cSAIC-Frederick, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA

^dHIV Drug Resistance Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA

Abstract

Two new monoterpene glycosides, distyloside A–B (**1–2**), and a new megastigmane glucoside, *iso*-dihydrodendranthemside A (**3**) were isolated from twigs and leaves of *Distylium racemosum*, along with five known phenolic compounds (**4–8**). The structures were established via spectroscopic techniques and chemical transformations, and the absolute stereochemistry of **3** was determined by Mosher's esterification. A homogeneous fluorescence resonance energy transfer (FRET) quenching assay was used to determine the inhibitory activity of isolates (**1–8**) on the ribonuclease H enzymes from HIV-1, 2, human, and *Escherichia coli*. Among them, 6''-*O*-galloylsalidroside (**6**) showed potent inhibitory effects with an IC₅₀ value of 3.5 μM on HIV-2, and 1.7 μM on human RNase H, respectively.

Keywords

Distylium racemosum; Monoterpene glycosides; Megastigmane glucoside; Ribonuclease H

Reverse transcription is the most vital process in the retroviral life cycle as a result of which reverse transcriptase (RT) has three different activities including RNA dependent DNA polymerase, DNA dependent DNA polymerase, and ribonuclease H (RNase H) activities.¹ Retroviral RNase H is necessary for the proliferation of retroviruses such as human immunodeficiency virus (HIV) and murine leukemia virus.² Inhibition of this enzyme has therefore been an important pharmaceutical target against diseases like AIDS. HIV, the causative agent of AIDS, is a dynamic virus that undergoes rapid genetic variation upon infecting a host, resulting in strains resistant to treatment.³ The rapid emergence of drug-

*Corresponding author. Tel.: +82 42 821 5933; fax: +82 42 823 6566. yhk@cnu.ac.kr (Y.H. Kim).

resistant variants of HIV demands the discovery of potent and selective anti-AIDS agents. However, the development of inhibitors of HIV RNase function has been slow and still has not resulted in clinical candidates.

Thus, we have sought potent antiviral components from natural sources since inhibitors of HIV remain an urgent priority. The methanol extract of *Distylium racemosum* Siebold & Zucc. (Hamamelidaceae), a small evergreen tree found on Jeju Island in South Korea,⁴ was found to completely inhibit RNase H enzymatic activity at the concentration of 50 µg/mL in a fluorescence resonance energy transfer (FRET) quenching assay.⁵ Herein, we report the phytochemical isolation and RNase H inhibition of components from the methanol extract of *D. racemosum*, and elucidated the structures of three new compounds **1-3** via spectroscopic techniques and chemical transformations.

The plant material was collected at Halla Mountain, Jeju Island, in December 2003 and taxonomically identified by one of the authors (Professor Young Ho Kim). A voucher specimen (CNU03152) was deposited at the Herbarium of the College of Pharmacy, Chungnam National University, Korea.

Preliminary examination of the crude methanol extract found that activity could be eluted from a polyamide column, indicating that tannins were not solely responsible for the observed activity.⁷

To obtain a bulk extract, twigs and leaves of *D. racemosum* (1.1 kg) were macerated three times with MeOH (10 L) at room temperature for 7 days. The solvent was concentrated in vacuo to give a greenish extract (70.0 g), which was suspended in H₂O and partitioned with CH₂Cl₂ and EtOAc to give a CH₂Cl₂-soluble fraction (14.0 g), an EtOAc-soluble fraction (12.0 g), and a H₂O-soluble fraction (44.0 g). In the enzymatic assay, the H₂O-fraction showed very strong inhibition of RNase H activity with an IC₅₀ value of 0.2 µg/mL. It was applied to a Diaion HP-20 column and eluted stepwise with mixtures of H₂O/MeOH (0, 25, 50, 75, 100%, v/v). Subsequent separations of the 25% MeOH fraction (F2, 8.0 g) were performed on reverse phase C-18, Sephadex LH-20, and silica gel columns⁸ to ultimately yield two new monoterpene glycosides, distyloside A–B (**1-2**), a new megastigmane glucoside, *iso*-dihydrodendranthemoside A (**3**), and five known phenolic compounds, (–)-epigallocatechin (**4**),⁹ salidroside (**5**),¹⁰ 6''-*O*-galloylsalidroside (**6**),¹¹ chlorogenic acid methyl ester (**7**),¹² and syringin (**8**)¹³ (Fig. 1).

Compound **1**¹⁴ was obtained as an amorphous powder with the molecular formula C₁₆H₃₀O₈, based on the positive HRESIMS (experimental m/z [M+Li]⁺ 357.2131, calculated 357.2101). Acid hydrolysis liberated D-glucose, which was identified by GC.¹⁵ The ¹H and ¹³C NMR spectral data (Table 1) showed the presence of three methyl singlets, three methylenes, two methines (one oxygenated), two oxygenated quaternary carbons, and a β-D-glucosyl unit. This was almost identical with (1*R*,2*R*,4*S*)-*p*-menthane-1,2,8-triol 8-*O*-β-D-glucopyranoside, except for a down-field shift difference for C-1 [δ 78.6 (+7.9)] and an up-field shift for C-8 [δ 71.7 (–8.0)].¹⁷ The HMBC spectrum of **1** confirmed that the position of the glucosyl unit attachment was at C-1 by the observed cross-peak between the anomeric H-1' and C-1 (Fig. 2). Furthermore, (1*S*,2*S*,4*R*)-*p*-menthane-1,2,8-triol 2-*O*-β-D-

glucopyranoside showed a positive optical rotation $[\alpha]_D^{21} +9.0$ (MeOH)¹⁸ contrary to those of (1*R*,2*R*,4*S*)-*p*-menthane-1,2,8-triol 8-*O*-β-D-glucopyranoside $[\alpha]_D^{23} -31.0$ (MeOH)¹⁷ and **1** $[\alpha]_D^{27} -31.0$ (MeOH).¹³ On the basis of this evidences, the structure of compound **1** was determined to be (1*R*,2*R*,4*S*)-*p*-menthane-1,2,8-triol 1-*O*-β-D-glucopyranoside, which was named distyloside A (**1**).

Compound **2**¹⁴ was obtained as an amorphous powder with the molecular formula C₂₁H₃₆O₁₁, based on HRESIMS (experimental m/z [M+Li]⁺ 471.2437, calculated 471.2418). Acid hydrolysis liberated D-glucose and D-xylose, which were identified by GC.¹⁵ A comparison of the ¹H- and ¹³C NMR spectroscopic data for **2** with those of (4*R*)-*p*-menth-1-ene-7,8-diol 7-*O*-β-D-glucopyranoside¹⁹ revealed the additional β-D-xylopyranosyl unit [δ 105.1 (C-1''), 72.3 (C-2''), 74.1 (C-3''), 69.4 (C-4''), 66.6 (C-5'') and δ 4.32 (1H, d, J = 6.5 Hz, H-1''), 3.60 (1H, m, H-2''), 3.52 (1H, m, H-3''), 3.80 (1H, m, H-4''), 3.53 (1H, m, H-5''), 3.86 (1H, dd, J = 3.0, 12.5 Hz, H-5'')] in the structure of **2**. From analysis of their HMBC correlations (Fig. 2), the linkage of xylose and glucose was confirmed to be β-D-xylopyranosyl-(1→6)-β-D-glucopyranosyl and the location of the glucosyl group was indicated to be at C-7. Enzymatic hydrolysis of **2** gave an aglycone [**2a**, C₁₀H₁₈O₂, an amorphous powder, $[\alpha]_D^{27} +43.1^\circ$ (c 0.1, MeOH)], which matched literature values for (4*R*)-*p*-menth-1-ene-7,8-diol¹⁹ and accordingly implied that **2** has the same absolute configuration. Therefore, compound **2** was determined to be (4*R*)-*p*-menth-1-ene-7,8-diol 7-*O*-[β-D-xylopyranosyl-(1→6)-β-D-glucopyranosyl] ester, which was named distyloside B (**2**).

Compound **3**¹⁴ was isolated as an amorphous powder and its molecular formula was determined to be C₂₁H₃₆O₁₁, based on HRESIMS (experimental m/z [M+Li]⁺ 399.2586, calculated 399.2570). Acid hydrolysis liberated D-glucose, which was identified by GC.¹⁵ The ¹H and ¹³C NMR spectral data (Table 1) indicated the presence of a β-D-glucopyranose unit and a megastigmane skeleton including two oxymethines (δ_C 69.7 and 75.4) and one oxygenated quaternary carbon (δ_C 77.7). Close inspection of COSY and HMBC spectrum (Fig. 2) established its structure to be megastigman-3,6,9-triol 3-*O*-β-D-glucopyranoside. Compound **3** showed similar chemical shift values in the ¹H and ¹³C NMR spectra with dihydrodendranthemside A, obtained by catalytically reducing dendranthemside A isolated from the leaves of *Alangium premnifolium*.²¹ But the main difference in ¹³C NMR spectral data was an up-field shift of C-4 [δ 35.0 (−4.0)] and C-5 [δ 31.4 (−5.6)], which indicated that **3** has an *S* orientation on C-5, not *R*. To confirm the stereochemistry of **3**, the glucose unit was removed by enzymatic hydrolysis.²⁰ The aglycone **3a** was separated into two equal portions and treated with (*S*)-(+)-*R*- and (*R*)-(−)-*R*-methoxy-*R*-(trifluoromethyl)phenylacetyl chloride in anhydrous pyridine at room temperature overnight, to afford the corresponding MTPA esters, respectively.²² As shown in Fig. 3, the δ values of the MTPA esters were consistent with 3*S* and 9*S* configurations, and NOESY correlations from H-3 to H-2 eq and H-13 supported the configuration of C-3 as well as C-5 to be 3*S* and 5*S*, respectively. In addition, H-2 ax was unambiguously correlated with H-4 but not with H-7, which gives supports a 6*R* assignment. On the basis of the evidence, the structure of **3**

was determined to be (3*S*,5*S*,6*R*,9*S*)-megastigman-3,6,9-triol 3-*O*-β-D-glucopyranoside, which was named as *iso*-dihydrodendranthemoside A (**3**).

To evaluate these compounds for antiviral activity, the isolates (**1-8**) were tested for inhibition of RNase H enzymatic activity from HIV-1, HIV-2, human, and *Escherichia coli* sources, using the RNase H FRET quenching assay as described previously.⁵ Among the eight compounds evaluated, 6''-*O*-galloylsalidroside (**6**) exhibited the most potent inhibitory activity with IC₅₀ values of 3.5 against HIV-2 and 1.7 μM against human RNase H, while (–)-epigallocatechin (**4**) showed moderate inhibition with IC₅₀ value of 16.4 μM against the human enzyme. HIV standard inhibitor, *N*-(3,4,5-trihydroxybenzoyl)-1-naphthaldehyde hydrazone (KMMP) was used as a positive control in this FRET assay. The IC₅₀ value of KMMP was 5.0 μM. Compound **6** (NSC# 741644) exhibited moderate effects with an IC₅₀ value of 17.4 μM against HIV-1 and the remaining compounds yielded negligible effects with IC₅₀ values more than 20.0 μM against all four RNase H RTs. In addition, none of the compounds inhibited the activity of *E. coli* RNase H in our assay system (Table 2).

This study indicated the structures (**4** and **6**) bearing a pyrogallolyl (1,2,3-trihydroxybenzyl) group might play an important role in inhibition of viral activity and is consistent with previous reports that polyphenolic tannins formed by polymerization of phenol, catechol, and pyrogallol precursors possess a range of biological activities, such as antioxidant, anti-carcinogenic, antiviral, and anti-inflammatory properties.²³

Thus, the present study suggests a potent possibility of contribution on antiviral properties by compound **6** isolated from *D. racemosum*.

Acknowledgments

This work was supported by Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0093815). This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract no. HHSN26120080001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This Research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

References and notes

1. Klumpp K; Mirzadegan T Curr. Pharm. Des 2006, 12, 1909. [PubMed: 16724956]
2. Himmel DM; Sarafianos SG; Dharmasena S; Hossain MM; McCoy-Simandle K; Ilina T; Clark AD Jr.; Knight JL; Julias JG; Clark PK; Krogh-Jespersen K; Levy RM; Hughes SH; Parniak MA; Arnold E ACS Chem. Biol 2006, 1, 702. [PubMed: 17184135]
3. Tramontano E; Esposito F; Badas R; Di Santo R; Costi R; La Colla P Antiviral Res. 2005, 65, 117. [PubMed: 15708638]
4. Ko RK; Lee S; Hyun C-G; Lee NH Bull. Korean Chem. Soc 2009, 30, 1376.
5. Ribonuclease H inhibitory assay: Inhibition assay was performed using an RNase H fluorescence resonance energy transfer (FRET) quenching assay previously reported.⁶ In brief, the assays were conducted with solutions of the RNA/DNA hybrid (50 mM Tris, pH 8.0, 60 mM KCl, and 5 mM MgCl₂) and 1.0 nM recombinant reverse transcriptase (each HIV-1, HIV-2, human, and *E. coli*). Reactions were initiated by adding each reverse transcriptase for 30 min at 37 °C and quenched by the addition of EDTA (0.5 M, pH 8.0). The fluorescence intensity of 96-well microplates was carried out using a SpectraMax Gemini XS dual-scanning microplate spectrofluorometer (Molecular

Devices, Sunnyvale, CA), and 384-well microplates was performed using a Victor2V multilabel plate reader (Perkin–Elmer Life Sciences, Boston, MA). To assess the effect of the inhibitors, 1 μ L of inhibitor in DMSO was added to the microplate well before adding the substrate and rt solutions. N-(3,4,5-Trihydroxybenzoyl)-1-naphthaldehyde hydrazone (KMMP) was used as a positive control in all assays.

6. Parniak MA; Min KL; Budihas SR; Le Grice SFJ; Beutler JA Anal. Biochem 2003, 322, 33. [PubMed: 14705777]
7. Cardellina JH II; Munro MHG; Fuller RW; Manfredi KP; McKee TC; Tischler M; Bokesch HR; Gustafson KR; Beutler JA; Boyd MR J. Nat. Prod 1993, 56, 1123. [PubMed: 8104236]
8. Isolation: The 25% MeOH fraction (F2, 8.0 g) was separated on an ODS C-18 column successively eluting with mixtures of H₂O/MeOH (1:0, 1:3, 1:1, 3:1, v/v) to yield three fractions (F21–F23). Fraction F21 (5.9 g) was partitioned on a Sephadex LH-20 column using pure MeOH as eluting solvent to give 4 (6.0 mg) and five fractions (F211–F215). The fraction F211 (130.1 mg) was further separated on a silica gel column using CH₂Cl₂/MeOH (10:1, v/v) as an eluent to yield five fractions (F2111–F2115). The fraction F2112 (5.0 mg) was purified by preparative ODS HPLC, using CH₃CN/H₂O (17:83, 3.0 mL/min) as solvent system to afford 8 (t_R 7.4 min, 1.2 mg). The fractions F2113 (22.7 mg) and F2115 (8.6 mg) were purified by ODS gel column chromatography with H₂O/MeOH (8:1, 9:1, v/v) as an eluent to give new compounds 3 (6.8 mg) and 1 (2.7 mg), respectively. The fraction F212 (1.2 g) was chromatographed on a silica gel column using a CH₂Cl₂/MeOH (1:1, 9:1, 8:2, v/v) as an eluent to yield seven fractions, F2121–F2127. The fraction F2125 (20.0 mg) was purified by preparative ODS HPLC, using CH₃CN/H₂O (20:80, 3.0 mL/min) as solvent system to afford 7 (t_R 9.8 min, 10.7 mg). The fraction of F2127 (68.0 mg) was chromatographed on a silica gel column using a CH₂Cl₂/MeOH (9:1, v/v) as an eluent to yield compound 5 (46.5 mg). Fraction F22 (1.3 g) was chromatographed over a Sephadex LH-20 column using pure MeOH as eluting solvent to afford six fractions (F221–F226). Further purification of the fractions F221 (484.0 mg) on a silica gel column using a CH₂Cl₂/MeOH (8:1, v/v) as an eluent resulted in the isolation of new compound 2 (7.2 mg). The fraction F223 (106.0 mg) was purified by preparative ODS HPLC, using CH₃CN/H₂O (18:82, 2.0 mL/min) as solvent system to afford 6 (t_R 7.8 min, 3.5 mg).
9. Kumar NS; Rajapaksha MJ Chromatogr., A 2005, 1083, 223.
10. Landtag J; Baumert A; Degenkolb T; Schmidt J; Wray V; Scheel D; Strack D; Rosahl S Phytochemistry 2002, 60, 683. [PubMed: 12127585]
11. Kim JI; Kim HH; Kim S; Lee KT; Ham IH; Whang WK Arch. Pharm. Res 2008, 31, 274. [PubMed: 18409038]
12. Zhu X; Dong X; Wang Y; Peng J; Luo S Helv. Chim. Acta 2005, 88, 339.
13. Youn U-J; Chen QC; Jin W-Y; Lee I-S; Kim H-J; Lee J-P; Chang M-J; Min B-S; Bae K-HJ Nat. Prod 2007, 70, 1687.
14. Distyloside A (1), NSC# 742190: an amorphous powder; $[\alpha]_D^{27}$ –31.0 (c 0.1, MeOH); ¹H NMR (C₅D₅N, 500 MHz) and ¹³C NMR (C₅D₅N, 125 MHz), see Table 1; ESIMS *m/z* 357.2 [M+Li]⁺; HRESIMS *m/z* 357.2131 [M+Li]⁺ (calcd for C₁₆H₃₀O₈Li, 357.2101). Distyloside B (2), NSC# 742191: an amorphous powder; $[\alpha]_D^{27}$ –18.2 (c 0.5, MeOH); ¹H NMR (CD₃OD, 500 MHz) and ¹³C NMR (CD₃OD, 125 MHz), see Table 1; ESIMS *m/z* 471.2 [M+Li]⁺; HRESIMS *m/z* 471.2437 [M+Li]⁺ (calcd for C₂₁H₃₆O₁₁Li, 471.2418). *iso*-Dihydrodendranthemoside (3), NSC# 742189: an amorphous powder; $[\alpha]_D^{27}$ –37.0 (c 0.1, MeOH); ¹H NMR (CD₃OD, 500 MHz) and ¹³C NMR (CD₃OD, 125 MHz), see Table 1; HRESIMS *m/z* 399.2586 [M+Li]⁺ (calcd for C₁₉H₃₆O₈Li, 399.2570).
15. Acid hydrolysis and sugar determination of compounds 1–3: Each compound (1–3, 0.1 mg) was dissolved in 6 N HCl (dioxane-H₂O, 1:1, v/v, 200 μ L) and then heated to 110 °C in a sand bath for 4 h. The reaction mixture was then concentrated to dryness under N₂ gas overnight. The residue was dissolved in 100 μ L of trimethylsilylimidazole and 100 μ L of pyridine. Heating at 60 °C was continued for 5 min, and the reaction mixture was evaporated to give a dried product, which was then partitioned between CH₂Cl₂ and H₂O (each 100 μ L). The CH₂Cl₂ layer was analyzed by GC procedure. The peaks of hydrolysates were detected at 14.11 min for d-glucose and 8.21 min d-xylose, respectively. The retention times of the authentic samples (Sigma-Aldrich), after being

treated in a similar manner, were 14.11 (d-glucose), 14.24 (l-glucose), 8.21 (d-xylose), and 8.66 min (l-xylose).

16. Kim JA; Yang SY; Koo J-E; Koh Y-S; Kim YH *Bioorg. Med. Chem. Lett* 2010, 20, 6703. [PubMed: 20932756]
17. Matsumura T; Ishikawa T; Kitajima J *Tetrahedron* 2001, 57, 8067.
18. Ishikawa T; Kudo M; Kitajima J *Chem. Pharm. Bull* 2002, 50, 501. [PubMed: 11963998]
19. Ishikawa T; Takayanagi T; Kitajima J *Chem. Pharm. Bull* 2002, 50, 1471. [PubMed: 12419912]
20. Enzymatic hydrolysis of 2 and 3: A mixture of each compound (2 and 3, 4.0 mg) and β -glucosidase (5 mg, TOYOBO Co., Ltd) in water (5.0 ml) was shaken in a water bath at 37 °C for 7 d. The mixture was concentrated in vacuo to dryness and the residue was chromatographed over silica gel eluting with CHCl₃–MeOH (9:1), to afford aglycones 2a (1.0 mg) and 3a (2.0 mg), respectively.
21. Otsuka H; Kamada K; Ogimi C; Hirata E; Takushi A; Takeda Y *Phytochemistry* 1994, 35, 1331.
22. Preparation of the (R)- and (S)-MTPA ester derivatives of compound 3a: Two portions (each 0.4 mg) of 3a were treated with either (S)-(+)-R- or (R)-(–)-R-methoxy-R(trifluoromethyl)phenylacetyl chloride (5.0 μ L) in anhydrous pyridine (50.0 μ L) at room temperature overnight. The reaction mixtures were purified over small silica gel columns with n-hexane-EtOAc (8:1) as the elution solvent, to afford the (R)- and (S)-MTPA ester derivatives of 3a, respectively. R-MTPA ester of 3a: δ 1.89 (1H, d, J = 14.0 Hz, H-2 ax), 1.26 (1H, d, J = 14.0 Hz, H-2 eq), 5.22 (1H, m, H-3), 1.83 (1H, m, H-4 ax), 1.53 (1H, m, H-4 eq), 1.29 (1H, m, H-5), 1.84 (1H, m, H-7 ax), 1.53 (1H, m, H-7 eq), 1.71 (1H, m, H-8 ax), 1.64 (1H, m, H-8 eq), 5.01 (1H, m, H-9), 1.25 (3H, J = 9.0 Hz, H-10), 1.84 (3H, s, H-11), 1.53 (3H, s, H-12), 0.85 (3H, J = 6.5 Hz, H-13). S-MTPA ester of 3a: δ 1.90 (1H, J = 14.0 Hz, H-2 ax), 1.33 (1H, d, J = 14.0 Hz, H-2 eq), 5.17 (1H, m, H-3), 1.67 (1H, m, H-4 ax), 1.41 (1H, m, H-4 eq), 1.30 (1H, m, H-5), 1.84 (1H, m, H-7 ax), 1.33 (1H, m, H-7 eq), 1.44 (1H, m, H-8 ax), 1.44 (1H, m, H-8 eq), 4.97 (1H, m, H-9), 1.31 (3H, J = 9.0 Hz, H-10), 0.79 (3H, s, H-11), 0.72 (3H, s, H-12), 0.62 (3H, J = 6.5 Hz, H-13).
23. Luo C; Grigsby W; Edmond N; Eastale A; Al-Hakkak JJ *Appl. Polym. Sci* 2010, 117, 352.

Figure 1.
Structures of compounds 1-8.

Figure 2.
Selected ^1H - ^1H COSY (–) and selected HMBC correlations ($\text{H} \rightarrow \text{C}$) of **1-3**.

Figure 3.
Diagnostic NOESY correlation of **3** (a) and results with the modified Mosher's methods
($\delta_S - \delta_R$) of **3a** (b).

Table 1

NMR data for compounds 1-3

No.	1^a		2^b		3^b	
	δ_C^c	δ_H^d (J in Hz)	δ_C^e	δ_H^d (J in Hz)	δ_C^e	δ_H^d (J in Hz)
1	78.6	—	135.5	—	39.9	—
2	72.9	4.37 m	126.6	5.76 m	43.4	2 ax 1.82 dd (14.0, 3.5) 2 eq 1.47 br d (14.0)
3	31.1	3 ax 2.30 m	27.8	3 ax 1.85 m	75.4	3.97 m
		3 eq 2.56 ddd (13.0, 13.0, 2.5)		3 eq 2.13 ddd (13.0, 3.0, 3.0)		
4	42.1	2.38 dddd (2.5, 2.5, 13.0, 13.0)	46.3	1.52 dddd (3.0, 3.0, 13.0, 13.0)	34.9	1.61 m
5	22.7	5 ax 1.86 ddd (2.5, 2.5, 13.0)	24.8	5 ax 1.23 ddd (4.0, 13.0, 13.0)	31.3	2.22 m
		5 eq 2.32 m		5 eq 1.94 d (13.0)		
6	31.2	6 ax 2.11 m, 6 eq 2.12 m	27.1	6 ax 2.03 dd (13.0, 16.0) 6 eq 2.24 dd (4.0, 16.0)	77.7	—
7	25.0	1.78 s	73.9	4.04 d (11.5), 4.16 d (11.5)	33.0	1.55 m, 1.80 m
8	71.7	—	73.1	—	35.9	1.58 m
9	28.0	1.40 s	27.8	1.15 s	69.7	3.64 m
10	27.6	1.39 s	26.3	1.14 s	23.4	0.93 d (8.5)
11					26.6	1.15 s
12					27.4	1.13 s
13					16.6	0.92 d (6.5)
1'	98.6	5.18 d (8.0)	102.7	4.23 d (8.0)	102.6	4.28 d (8.0)
2'	75.6	4.04 m	75.0	3.19 m	75.3	3.14 m
3'	79.1	4.25 m	77.9	3.33 m	78.4	3.34 m
4'	72.0	4.21 m	71.6	3.33 m	71.7	3.27 m
5'	78.1	3.94 m	76.8	3.39 m	77.7	3.23 m
6'	63.0	4.33 m, 4.49 m	69.4	3.72 dd (5.5, 11.5) 4.08 dd (2.0, 11.5)	62.8	3.65 dd (5.5, 12.0) 3.84 dd (2.0, 12.0)
1''			105.1	4.32 d (6.5)		
2''			72.3	3.60 dd (7.0, 17.5)		
3''			74.1	3.52 m		

d Recorded at 500 MHz.

Table 2Inhibitory activity of isolated compounds (**1-8**) on ribonuclease H

Compounds	RNase H IC ₅₀ ^a (μM)			
	HIV-1	HIV-2	Human	<i>E. coli</i>
1	>20.0	>20.0	>20.0	>20.0
2	>20.0	>20.0	>20.0	>20.0
3	>20.0	>20.0	>20.0	>20.0
4	>20.0	>20.0	16.4	>20.0
5	>20.0	>20.0	>20.0	>20.0
6	17.4	3.5	1.7	>20.0
7	>20.0	>20.0	>20.0	>20.0
8	>20.0	>20.0	>20.0	>20.0
KMMP ^b	5.0			

^a All data are derived from triplicate tests with the variation of the mean averaging 10%.^b *N*-(3,4,5-Trihydroxybenzoyl)-1-naphthaldehyde hydrazone, positive control (*n* = 8).